Detecting pancreatic cancer early using biomarker tests
Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers (UroPanc)
Queen Mary University of London · NCT04449406
This study is testing if new urine and blood tests can help find pancreatic cancer earlier in people who have symptoms or are at risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Queen Mary University of London (other) |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 4 sites (Liverpool and 3 other locations) |
| Trial ID | NCT04449406 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop an accurate diagnostic method for pancreatic ductal adenocarcinoma (PDAC) by analyzing urine and blood samples from both symptomatic patients and asymptomatic individuals at risk. The research focuses on a panel of urinary biomarkers (LYVE1, REG1B, TFF1) and the PancRISK score, in conjunction with plasma CA19-9 levels. The collected samples will be compared against imaging and histopathology data to create a predictive model for earlier detection of PDAC. The study seeks to improve diagnostic accuracy and potentially enhance early intervention strategies.
Who should consider this trial
Good fit: Ideal candidates include symptomatic individuals with suspected pancreatic diseases and asymptomatic individuals identified through the EUROPAC registry.
Not a fit: Patients who have received treatment for any malignancy other than basal cell carcinoma within the last five years may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate detection of pancreatic cancer, improving patient outcomes.
How similar studies have performed: Other studies have explored biomarker panels for cancer detection, showing promise, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria (Symptomatic patients): * Able and willing to give informed consent * ≥18 years old * Suspected pancreatic diseases with symptoms including, but not limited to, diarrhoea, back pain, abdominal pain, nausea, vomiting, constipation or new onset diabetes Exclusion criteria (Symptomatic patients): * Current or prior treatment (chemotherapy, radiotherapy, surgical resection, biological therapy, and immunotherapy) for any malignancy other than basal cell carcinoma within 5 years of enrolment. Asymptomatic participants will be identified through the EUROPAC registry and will fulfil EUROPAC's eligibility criteria.
Where this trial is running
Liverpool and 3 other locations
- EUROPAC study, University of Liverpool — Liverpool, United Kingdom (ACTIVE_NOT_RECRUITING)
- ADEPTS study, University College London — London, United Kingdom (ACTIVE_NOT_RECRUITING)
- Imperial College London — London, United Kingdom (ACTIVE_NOT_RECRUITING)
- Royal London Hospital — London, United Kingdom (RECRUITING)
Study contacts
- Principal investigator: Tatjana Crnogorac-Jurcevic, MD, PhD — Queen Mary University of London
- Study coordinator: UroPanc Coordinator
- Email: bci-uropanc@qmul.ac.uk
- Phone: 020 7882 8497
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreatic Ductal Adenocarcinoma, Biomarker, PDAC, Pancreatic cancer, CA19-9, Urine